鹅去氧胆酸
分析标准品,HPLC≥98%
Chenodeoxycholic acid
CAS号:474-25-9
分子式:C24H40O4
分子量:392.58
MDL:MFCD00064142
别名:脱氧鹅胆酸;鹅脱氧胆酸;3α,7α-二羟基胆质酸;3α,7α-二羟基-5-β-胆烷酸
货号 | 规格/参数/品牌 | 价格 | 货期 |
YJ-B20347-20mg | 分析标准品,HPLC≥98% | ¥350.00 | 现货 |
JS25542-5g | 98% | ¥160.00 | 现货 |
JS25542-25g | 98% | ¥270.00 | 现货 |
JS25542-100g | 98% | ¥650.00 | 现货 |
产品介绍
鹅去氧胆酸是一种疏水初级胆汁酸,能够活化核受体 FXR,该受体与胆固醇代谢有关。 生物活性:
Chenodeoxycholic Acid 是一种疏水初级胆汁酸,能够活化核受体 FXR,该受体与胆固醇代谢有关。鹅去氧胆酸(CDCA)和脱氧胆酸(DCA)均能抑制11 beta HSD2,IC50值分别为22mM和38mM,并引起皮质醇依赖性核易位,增加盐皮质激素受体(MR)的转录活性。鹅去氧胆酸能够通过激活膜G蛋白偶联受体(TGR5)依赖途径,诱导细胞周期蛋白d1蛋白和mRNA表达的显著增加,从而刺激Ishikawa细胞的生长。鹅去氧胆酸(CDCA)在培养的人肝母细胞瘤细胞系HepG2中诱导低密度脂蛋白受体mRNA水平约为4倍,高密度脂蛋白辅酶A还原酶和高密度脂蛋白辅酶A合成酶的mRNA水平为2倍。氯去氧胆酸诱导的ISC(≥67%)被布美他尼、Bacl2和囊性纤维化跨膜电导调节器(CFTR)抑制剂cftrinh-172抑制。腺苷酸环化酶抑制剂MDL12330A使鹅去氧胆酸刺激的ISC降低43%,鹅去氧胆酸增加细胞内cAMP浓度。鹅去氧胆酸处理激活c/ebpβ,如其磷酸化、核积累和在hepg2细胞中的表达增加所示。Chenodeoxycholic acid增强含有-1.65-kb GSTA2启动子的构建体的荧光素酶基因转录,该启动子含有C / EBP反应元件(pGL-1651)。鹅去氧胆酸处理激活AMP激活蛋白激酶(AMPK),导致细胞外信号调节激酶1/2(ERK1/2)激活,实验结果证明了使用AMPKα的显性负突变体和化学抑制剂。
熔点:165-167℃
沸点:547.1 ℃ at 760 mmHg
比旋光度:12 º (c=1, CHCl3)
外观:白色粉末
溶解性:几乎不溶于水,易溶于乙醇、冰乙酸、微溶于氯仿。
敏感性:对光敏感
储存条件:2-8℃
注意:部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。
参考文献(41篇)
41. [IF=3.1] Dan Yang et al."The defense role of luteolin-β-CD-MOF against acetaminophen induced liver toxicity by regulating of bile acids metabolism and gut microbiota."JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS.2025 Nov;265:117033
40. [IF=5.4] Yunhua Liu et al."Molecular Mechanisms of Potentilla Discolor Bunge in Regulating Ferroptosis to Alleviate DKD via the Nrf2 Signaling Pathway."JOURNAL OF ETHNOPHARMACOLOGY.2025 May;:120035
39. [IF=4.4] Yanruyu Feng et al."Integrative analysis of non12-hydroxylated bile acid revealed the suppressed molecular map of alternative pathway in nonalcoholic steatohepatitis mice."FASEB JOURNAL.2024 Nov;38(22):e70167
38. [IF=4.9] Donglin Du et al."Exploring the CDCA-Scd1 Axis: Molecular Mechanisms Linking the Colitis Microbiome to Neurological Deficits."INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.2025 Jan;26(5):2111
37. [IF=5.1] Yilong Liu et al."Myricetin alleviates high-fat diet-induced atherosclerosis in ApoE−/− mice by regulating bile acid metabolism involved in gut microbiota remodeling."Food & Function.2025 Mar;:
36. [IF=5.3] Tong Tian-Tian et al."Pharmacological effects of bile acids on polycystic ovary syndrome via the regulation of chemerin."Chinese Medicine.2025 Dec;20(1):1-19
35. [IF=3.2] Jingjing Lu et al."The adaptive mechanism of Ctenopharyngodon idellus to dietary lipid levels: Insights from microbiota-mediated bile acid enterohepatic circulation."Aquaculture Reports.2025 Jul;42:102796
34. [IF=6.9] Dongmei Qin et al."Lupeol improves bile acid metabolism and metabolic dysfunction-associated steatotic liver disease in mice via FXR signaling pathway and gut-liver axis."BIOMEDICINE & PHARMACOTHERAPY.2024 Aug;177:116942
33. [IF=5.4] Yingkun Sheng et al."Dan-shen Yin promotes bile acid metabolism and excretion to prevent atherosclerosis via activating FXR/BSEP signaling pathway."JOURNAL OF ETHNOPHARMACOLOGY".2024 Apr;:118209
32. [IF=5.6] Dan Yang et al."Luteolin-β-CD-MOF prevents against acetaminophen-mediated liver damage by controlling ferroptosis through GSH/GPX4/SLC7A11 signal axis."Journal of Functional Foods".2024 May;116:106138
31. [IF=6.1] Shurui Zhang et al."Lactiplantibacillus plantarum ATCC8014 Alleviates Postmenopausal Hypercholesterolemia in Mice by Remodeling Intestinal Microbiota to Increase Secondary Bile Acid Excretion."JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY".2024;72(12):6236–6
30. [IF=4.9] Huang Hefei et al."Tanreqing injection inhibits dengue virus encephalitis by suppressing the activation of NLRP3 inflammasome."Chinese Medicine".2024 Dec;19(1):1-17
29. [IF=5.6] Shengyun Dai et al."Synergistic effect of Euphorbia kansui stir-fried with vinegar and bile acids on malignant ascites effusion through modulation of gut microbiota."Frontiers in Pharmacology.2023; 14: 1249910
28. [IF=3.9] Ya-nan Ou-Yang et al."High-salt diet induces dyslipidemia through the SREBP2/PCSK9 pathway in dahl salt-sensitive rats."BIOCHIMIE.2023 Oct;:
27. [IF=6.1] Sensen Chi et al."Time-restricted feeding alleviates metabolic implications of circadian disruption by regulating gut hormone release and brown fat activation."Food & Function.2023 Oct;:
26. [IF=7.9] Mei-Qi Wang et al."Wedelolactone alleviates cholestatic liver injury by regulating FXR-bile acid-NF-κB/NRF2 axis to reduce bile acid accumulation and its subsequent inflammation and oxidative stress."PHYTOMEDICINE.10.1016/j.phymed.2023.155124
25. [IF=4.6] Wei Li et al."Characterization of Metabolic Correlations of Ursodeoxycholic Acid with Other Bile Acid Species through In Vitro Sequential Metabolism and Isomer-Focused Identification."MOLECULES.2023 Jan;28(12):4801
24. [IF=4.212] Yingkun Sheng et al."PARP-1 inhibitor alleviates liver lipid accumulation of atherosclerosis via modulating bile acid metabolism and gut microbes."Molecular Omics.2023 May;:
23. [IF=6.911] Yan-Zhen Wang et al."A strategy for screening and identification of new amino acid-conjugated bile acids with high coverage by liquid chromatography-mass spectrometry."ANALYTICA CHIMICA ACTA.2023 Jan;1239:340691
22. [IF=7.675] Lei Xu et al."Chenodeoxycholic Acid (CDCA) Promoted Intestinal Epithelial Cell Proliferation by Regulating Cell Cycle Progression and Mitochondrial Biogenesis in IPEC-J2 Cells."Antioxidants.2022 Nov;11(11):2285
21. [IF=4.571] Yuanjie Wen et al."The role of the farnesoid X receptor in quadruple anti-tuberculosis drug-induced liver injury."TOXICOLOGY.2022 Jun;476:153256
20. [IF=6.558] Yan Cao et al."Widely quasi-quantitative analysis enables temporal bile acids-targeted metabolomics in rat after oral administration of ursodeoxycholic acid."ANALYTICA CHIMICA ACTA. 2022 Jun;1212:339885
19. [IF=5.396] Juan Wu et al."Sargassum fusiforme polysaccharide is a potential auxiliary substance for metformin in the management of diabetes."Food Funct. 2022 Feb;:
18. [IF=3.935] Runjing Zhang et al."Xiaoyan lidan formula ameliorates α-naphthylisothiocyanate-induced intrahepatic cholestatic liver injury in rats as revealed by non-targeted and targeted metabolomics."J Pharmaceut Biomed. 2020 Feb;179:112966
17. [IF=3.935] Song Lin et al."A systemic combined nontargeted and targeted LC-MS based metabolomic strategy of plasma and liver on pathology exploration of alpha-naphthylisothiocyanate induced cholestatic liver injury in mice."J Pharmaceut Biomed. 2019 Jul;171:180
16. [IF=3.935] Song Lin et al."A systemic combined nontargeted and targeted LC-MS based metabolomic strategy of plasma and liver on pathology exploration of alpha-naphthylisothiocyanate induced cholestatic liver injury in mice."J Pharmaceut Biomed. 2019 Jul;171:180
15. [IF=5.34] Kaihui Zhang et al."A UPLC-MS/MS-based metabolomics analysis of the pharmacological mechanisms of rabdosia serra against cholestasis."Phytomedicine. 2021 Oct;91:153683
14. [IF=5.396] Cong Liang et al."Lactiplantibacillus plantarum H-87 prevents high-fat diet-induced obesity by regulating bile acid metabolism in C57BL/6J mice."Food Funct. 2021 May;12(10):4315-4324
13. [IF=5.396] Shiming Huang et al."A sulfated polysaccharide from Gracilaria Lemaneiformis regulates cholesterol and bile acid metabolism in high-fat diet mice."Food Funct. 2019 Jun;10(6):3224-3236
12. [IF=5.81] Shujing Lv et al."The Study on the Mechanism of Hugan Tablets in Treating Drug-Induced Liver Injury Induced by Atorvastatin."Front Pharmacol. 2021; 12: 683707
11. [IF=5.81] Li Peng et al."Detection of Vasodilators From Herbal Components by a Transcriptome-Based Functional Gene Module Reference Approach."Front Pharmacol. 2019 Oct;0:1144
10. [IF=3.935] Ziying Liu et al."Promotion of classic neutral bile acids synthesis pathway is responsible for cholesterol-lowing effect of Si-miao-yong-an decoction: Application of LC–MS/MS method to determine 6 major bile acids in rat liver and plasma."J Pharmaceut Bio
9. 曹妍,李婷,常安琪,蒋珍珍,于娟,屠鹏飞,宋月林.蛇胆中胆汁酸类化学成分分析[J].中国中药杂志,2021,46(01):130-138.
8. 李玮,蒋珍珍,李菡,屠鹏飞,宋青青,于娟,宋月林.利用在线加压溶剂提取-超高效液相色谱-离子阱-飞行时间-质谱法定性分析片仔癀化学成分组[J].色谱,2021,39(05):478-487.
7. 曹妍, 宋青青, 李军,等. 牦牛胆中胆汁酸类化学成分分析[J]. 中国中药杂志 2019年44卷12期, 2538-2543页, MEDLINE ISTIC PKU CSCD CA BP, 2019.
6. 陈云, 陈劲松, 郁红礼,等. 胆南星发酵制品与混合蒸制品的鉴别研究[J]. 世界中医药, 2019, v.14(02):42-45+50.
5. 陈云 郁红礼 吴皓 等. 发酵对胆南星中胆汁酸类成分的影响及胆南星中3种游离胆汁酸含量测定研究[J]. 中国中药杂志 2018 43(22):99-103.
4. 陈江宁, 单国顺, 刘晓瑜,等. 胆南星辅料成分分析及其清热作用[J]. 中国现代中药 2016年18卷7期, 837-840页, ISTIC CA, 2016.
3. 席晓志, 李佳, 郭莎莎,等. 鹅去氧胆酸的大孔树脂纯化工艺优化及其降血脂活性[J]. 现代食品科技, 2018, 034(008):123-129.
2. 赵启苗, 单国顺, 陈江宁,等. 胆南星质量评价方法初探[J]. 中国实验方剂学杂志, 2017(06):28-31.
1. 陈江宁 单国顺 赵启苗 等. 不同胆汁制胆南星中胆酸类成分及其解热作用比较[J]. 现代药物与临床 2017 32(004):567-571.
从2011年开始我们致力于在生命科学领域、生物医学实验技术及论文润色服务,协助客户各类实验服务及论文润色十余年,是客户您值得信赖的科研合作伙伴!
如果您受时间、试验条件等限制而无法完成您的课题研究,欢迎您与我们联系。
实验技术服务:
